ASMB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ASMB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2025-03-02), Assembly Biosciences's current share price is $12.86. Assembly Biosciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 was $12.43. Assembly Biosciences's Cyclically Adjusted PS Ratio for today is 1.03.
The historical rank and industry rank for Assembly Biosciences's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, Assembly Biosciences's highest Cyclically Adjusted PS Ratio was 45.56. The lowest was 0.73. And the median was 16.90.
ASMB's Cyclically Adjusted PS Ratio is ranked better thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Assembly Biosciences's adjusted revenue per share data for the three months ended in Sep. 2024 was $1.078. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $12.43 for the trailing ten years ended in Sep. 2024.
The historical data trend for Assembly Biosciences's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Assembly Biosciences Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | 0.74 | 1.02 | 1.07 | 1.22 |
For the Biotechnology subindustry, Assembly Biosciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Assembly Biosciences's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Assembly Biosciences's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 12.86 | / | 12.43 | |
= | 1.03 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Assembly Biosciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 is calculated as:
For example, Assembly Biosciences's adjusted Revenue per Share data for the three months ended in Sep. 2024 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Sep. 2024 (Change) | * | Current CPI (Sep. 2024) |
= | 1.078 | / | 133.0289 | * | 133.0289 | |
= | 1.078 |
Current CPI (Sep. 2024) = 133.0289.
Assembly Biosciences Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201412 | 0.000 | 99.070 | 0.000 |
201503 | 0.000 | 99.621 | 0.000 |
201506 | 0.000 | 100.684 | 0.000 |
201509 | 0.000 | 100.392 | 0.000 |
201512 | 0.000 | 99.792 | 0.000 |
201603 | 0.000 | 100.470 | 0.000 |
201606 | 0.000 | 101.688 | 0.000 |
201609 | 0.000 | 101.861 | 0.000 |
201612 | 0.000 | 101.863 | 0.000 |
201703 | 0.475 | 102.862 | 0.614 |
201706 | 1.633 | 103.349 | 2.102 |
201709 | 1.838 | 104.136 | 2.348 |
201712 | 2.092 | 104.011 | 2.676 |
201803 | 2.114 | 105.290 | 2.671 |
201806 | 1.880 | 106.317 | 2.352 |
201809 | 2.068 | 106.507 | 2.583 |
201812 | 1.758 | 105.998 | 2.206 |
201903 | 1.816 | 107.251 | 2.252 |
201906 | 1.436 | 108.070 | 1.768 |
201909 | 1.960 | 108.329 | 2.407 |
201912 | 2.061 | 108.420 | 2.529 |
202003 | 1.396 | 108.902 | 1.705 |
202006 | 12.669 | 108.767 | 15.495 |
202009 | 11.697 | 109.815 | 14.170 |
202012 | 0.348 | 109.897 | 0.421 |
202103 | 0.000 | 111.754 | 0.000 |
202106 | 0.000 | 114.631 | 0.000 |
202109 | 1.647 | 115.734 | 1.893 |
202112 | 0.000 | 117.630 | 0.000 |
202203 | 0.000 | 121.301 | 0.000 |
202206 | 0.000 | 125.017 | 0.000 |
202209 | 0.000 | 125.227 | 0.000 |
202212 | 0.000 | 125.222 | 0.000 |
202303 | 0.000 | 127.348 | 0.000 |
202306 | 0.000 | 128.729 | 0.000 |
202309 | 0.000 | 129.860 | 0.000 |
202312 | 1.346 | 129.419 | 1.384 |
202403 | 1.055 | 131.776 | 1.065 |
202406 | 1.512 | 132.554 | 1.517 |
202409 | 1.078 | 133.029 | 1.078 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Assembly Biosciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael Houghton | director | C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD., FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Gilead Sciences Inc | 10 percent owner | 333 LAKESIDE DR, FOSTER CITY CA 94404 |
Alexander Schornstein | 10 percent owner | KAISER-FRIEDRICH-ALLEE 2, AACHEN 2M 52074 |
Nicole S White | officer: Chief Manufacturing Officer | C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD., FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Jason A Okazaki | officer: Chief Legal & Business Officer | C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD, FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Jeanette M Bjorkquist | officer: Principal Accounting Officer | C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD, FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080 |
John G Mchutchison | director, officer: CEO and President | 333 LAKESIDE DRIVE, FOSTER CITY X1 94404 |
Delaney William E Iv | officer: CSO, Virology | C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD, FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Michael P. Samar | officer: See Remarks | C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN ST. SUITE 310, CARMEL IN 46032 |
Luisa M Stamm | officer: Chief Medical Officer | C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN ST, SUITE 310, CARMEL IN 46032 |
Lisa Johnson-pratt | director | C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122 |
Jacqueline Sybil Papkoff | officer: See remarks | C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN STREET, SUITE 310, CARMEL IN 46032 |
Gina Consylman | director | C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Richard James Colonno | officer: Chief Science Officer | ASSEMBLY BIOSCIENCES, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158 |
Thomas Joseph Russo | officer: CFO | C/O ASSEMBLY BIOSCIENCES, INC., 11711 N MERIDIAN ST, SUITE 310, CARMEL IN 46032 |
From GuruFocus
By Marketwired • 06-17-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By PRNewswire • 10-18-2023
By Marketwired • 07-15-2024
By GuruFocus Research • 02-06-2024
By Marketwired • 06-18-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024